AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC, HCC, immunologically cold tumors, and CCA. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; and AstraZeneca PLC. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
AVEO Pharmaceuticals Trading Down 2.4 %
Shares of NASDAQ:AVEO traded down $0.19 on Wednesday, reaching $7.74. 207,127 shares of the company traded hands, compared to its average volume of 285,817. The business's 50-day simple moving average is $6.49 and its 200 day simple moving average is $5.19. AVEO Pharmaceuticals has a 52 week low of $3.06 and a 52 week high of $8.25. The stock has a market capitalization of $267.91 million, a P/E ratio of -7.55 and a beta of 0.79. The company has a current ratio of 3.10, a quick ratio of 3.06 and a debt-to-equity ratio of 1.09.
AVEO Pharmaceuticals (NASDAQ:AVEO - Get Rating) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.04. AVEO Pharmaceuticals had a negative return on equity of 87.81% and a negative net margin of 45.72%. During the same period in the previous year, the firm earned ($0.48) EPS. As a group, equities analysts anticipate that AVEO Pharmaceuticals will post -0.94 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of brokerages recently issued reports on AVEO. StockNews.com upgraded AVEO Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Monday. SVB Leerink reissued an "outperform" rating on shares of AVEO Pharmaceuticals in a research note on Wednesday, July 27th.